Dr. Eunice Wang, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 66
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 214903 -
Hematology (Internal Medicine) Physician
NY license 214903
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Olean General Hospital Olean, NY
Medical groups
- Roswell PArk Cancer Institute (488 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 176
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 77 | 29 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 61 | 12 |
| Established patient office or other outpatient visit, 40-54 minutes | 58 | 34 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 29 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 23 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 20 |
| Hydroxyurea Other prescribers in Buffalo, NY | 14 |
| Ojjaara (momelotinib dihydrochloride) | 13 |
| Tibsovo (ivosidenib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 24 payments worth $22,900 in total to this clinician.
| Astellas Pharma US Inc | $7,873 |
|---|---|
| AbbVie Inc. | $4,717 |
| Stemline Therapeutics Inc. | $3,120 |
| Janssen Scientific Affairs, LLC | $2,806 |
| Novartis Pharmaceuticals Corporation | $2,450 |
| Daiichi Sankyo Inc. | $1,544 |
| Pfizer Inc. | $139 |
| Syndax Pharmaceuticals, Inc. | $127 |
| Consulting Fee | $20,951 |
|---|---|
| Food and Beverage | $1,034 |
| Travel and Lodging | $915 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 9, 2025 | Consulting Fee Xospata · Oncology | $7,710 |
| Stemline Therapeutics Inc. Jun 13, 2025 | Consulting Fee ELZONRIS · Oncology | $3,120 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Novartis Pharmaceuticals Corporation Jul 11, 2025 | Consulting Fee | $2,450 |
| AbbVie Inc. Nov 5, 2025 | Consulting Fee | $2,175 |
| Daiichi Sankyo Inc. Jan 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,544 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee | $725 |
| AbbVie Inc. Jul 4, 2025 | Consulting Fee | $725 |
| AbbVie Inc. Oct 13, 2025 | Travel and Lodging travel to NEW YORK, NY · in-kind Company’s descriptionM26-092 | $702 |
| AbbVie Inc. Nov 5, 2025 | Travel and Lodging travel to NEW YORK, NY · in-kind | $183 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 9, 2025 | Consulting Fee Xospata · Oncology | $7,710 |
| Astellas Pharma US Inc Dec 9, 2025 | Travel and Lodging Xospata · Oncology · travel to Orlando, FL | $29.67 |
| AbbVie Inc. Nov 5, 2025 | Consulting Fee | $2,175 |
| AbbVie Inc. Nov 5, 2025 | Travel and Lodging travel to NEW YORK, NY · in-kind | $183 |
| AbbVie Inc. Oct 13, 2025 | Travel and Lodging travel to NEW YORK, NY · in-kind Company’s descriptionM26-092 | $702 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Novartis Pharmaceuticals Corporation Jul 11, 2025 | Consulting Fee | $2,450 |
| AbbVie Inc. Jul 4, 2025 | Consulting Fee | $725 |
| Stemline Therapeutics Inc. Jun 13, 2025 | Consulting Fee ELZONRIS · Oncology | $3,120 |
| Daiichi Sankyo Inc. Jan 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,544 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee | $725 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $130,830 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
Astellas Pharma Global Development - A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda Pharmaceuticals U.S.A., Inc. · Active, not recruiting · NCT03589326 - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NP…
Janssen Research & Development, LLC - STML-401-0423 - a phase ii multicenter open -label trial of tagraxofusp (tag) in combination with venetoclax and azacitidine (ven/aza) in adults with previously untreated CD123+ acute myeloid leukemia (aml) who are i…
Stemline Therapeutics Inc. - IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie Inc. · Active, not recruiting · NCT04086264 - Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.